Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12624000909527
Ethics application status
Approved
Date submitted
17/05/2024
Date registered
25/07/2024
Date last updated
25/07/2024
Date data sharing statement initially provided
25/07/2024
Date results provided
25/07/2024
Type of registration
Retrospectively registered

Titles & IDs
Public title
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Djibouti-ville, Djibout
Scientific title
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Djibouti-ville, Djibout
Secondary ID [1] 312169 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record
ACTRN12624000526572 is a study conducted in Yemen while 387824 is study just completed in Djibouti.

Health condition
Health condition(s) or problem(s) studied:
Malaria 333819 0
Condition category
Condition code
Infection 330489 330489 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This was a single arm prospective study to assess the efficacy and safety of artemether-lumefantrine. Tablets containing 20 mg artemether and 120 mg lumefantrine in each tablet was given twice daily for three consecutive days according to the recommended weight bands: 1 tablet to those weighing 5 to 14 kg; 2 tablets for 15 to 24 kg; 3 tablets for 25 to 34 kg and 4 tablets for equal or greater than 35 kg. The total target dose ranges were 5-24 mg/kg body weight (bw)of artemether and 29-144 mg/kg bw of lumefantrine. All treatments was given orally under direct supervision by the study nurse. Patients were followed up for 28 days. For children, tablets were crushed and added to water in spoon and given to them.
Intervention code [1] 328612 0
Treatment: Drugs
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 338261 0
Proportion of treatment failures (early treatment failure + late clinical failure+late parasitological failure). This is a composite primary outcome.
Timepoint [1] 338261 0
Days 0 (prior to treatment), 1, 2 (during treatment),3, 7, 14, 21, 28 (post-treatment) for artemether-lumefantrine
Secondary outcome [1] 435196 0
Percent of adverse event following treatment of artemether-lumefantrine or dihydroartesmisinin-piperaquine will be investigated.
The known adverse events of atemether-lumefantrine are abdominal pain, asthenia, cough, diarrhoea, dizziness, fever, headache, joint and muscle pain, loss of appetite, rush, nausea, vomiting. Those for dihydroartemisinin include asthenia, cough, diarrhoea, fever, loss of appetite, nausea, vomiting.
Timepoint [1] 435196 0
Days 0 (prior to treatment), 1, 2 (during treatment),3, 7, 14, 21, 28 (post-treatment) for artemether-lumefantrine

Eligibility
Key inclusion criteria
• age between 6 months and above;;
• mono-infection with P. falciparum confirmed by positive blood smear (i.e. no mixed infection);
• parasitaemia of 500-200000 per micrometer asexual forms;
• presence of axillary temperature greater or equal 37.5 degrees centigrade or history of fever during the past 24 h;
• ability to swallow oral medication;
• ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
• informed consent from the patient or from a parent or guardian in the case of children aged less than 18 years;
• informed assent from any minor participant aged from 12 to age of majority years; and
Minimum age
6 Months
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
• presence of general danger signs in children aged under 12 years or signs of severe falciparum malaria according to the definitions of WHO;
• weight under 5 kg;
• haemoglobin below 8 g per deciliter;
• mixed or mono-infection with another Plasmodium species detected by microscopy;
• presence of severe malnutrition defined as a child aged between 6-60 months who has a mid-upper arm circumference below 115 mm);
• presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
• regular medication, which may interfere with antimalarial pharmacokinetics;
• history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
• a positive pregnancy test or breastfeeding; and

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 4
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Data was double entered by two independent data clerks using WHO database Excel programme, Data was analysed by both Kaplan-Meier and per-protocol methods. Patients were censored or excluded from the analysis if they were withdrawn or lost to follow-up or PCR results were unclassifiable or if the results of PCR indicate that the failure is due to reinfection with P. falciparum or P. vivax.

The final analysis will include:
• a description of all patients screened and the distribution of reasons for non-inclusion in the study;
• a description of all the patients included in the study;
• the proportion of adverse events and serious adverse events in all the patients included in the study;
• Prevalence of mutations in k13 gene associated with artemisinin partial resistance.;
• the proportion of patients lost to follow-up or withdrawn, with 95% confidence intervals and a list of reasons for withdrawal;
• the cumulative incidence of success and failure rates at day 28, PCR-uncorrected and PCR-corrected; and
• the proportion of early treatment failure, late clinical failure, late parasitological failure and adequate clinical and parasitological response at day 28, with 95% confidence intervals, PCR-uncorrected and PCR-corrected

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
28/02/2024
Date of last participant enrolment
Anticipated
Actual
16/03/2024
Date of last data collection
Anticipated
Actual
13/04/2024
Sample size
Target
88
Accrual to date
Final
95
Recruitment outside Australia
Country [1] 26312 0
Djibouti
State/province [1] 26312 0
Djibouti

Funding & Sponsors
Funding source category [1] 316535 0
Government body
Name [1] 316535 0
Ministry of Health of Djibouti
Country [1] 316535 0
Djibouti
Primary sponsor type
Government body
Name
Ministry of Health of Djibouti
Address
Country
Djibouti
Secondary sponsor category [1] 318715 0
None
Name [1] 318715 0
Address [1] 318715 0
Country [1] 318715 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 315328 0
Eastern Mediterranean Regional Ethics Research Committee (EMR-RERC
Ethics committee address [1] 315328 0
Ethics committee country [1] 315328 0
Djibouti
Date submitted for ethics approval [1] 315328 0
26/09/2023
Approval date [1] 315328 0
06/10/2023
Ethics approval number [1] 315328 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 134354 0
Mr Samatar Kayad Guelleh
Address 134354 0
National Malaria Control Programme, Avenue George Clemenceau, P.O. Box 1974, Djibouti city, Djibouti region
Country 134354 0
Djibouti
Phone 134354 0
+25377705311
Fax 134354 0
Email 134354 0
[email protected]
Contact person for public queries
Name 134355 0
Samatar Kayad Guelleh
Address 134355 0
National Malaria Control Programme, Avenue George Clemenceau, P.O. Box 1974, Djibouti city, Djibouti region
Country 134355 0
Djibouti
Phone 134355 0
+25377705311
Fax 134355 0
Email 134355 0
[email protected]
Contact person for scientific queries
Name 134356 0
Marian Warsame
Address 134356 0
Department of Public Health and Community Medicine, Medicinaregatan 18A, 41390 Göteborg
Country 134356 0
Sweden
Phone 134356 0
+46760525254
Fax 134356 0
Email 134356 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
Documents were uploaded by study researchers but have since been removed.

Documents added automatically
No additional documents have been identified.